North America Pharmaceutical Packaging Market 2020-2027 by Packaging Category (Primary, Secondary, Tertiary), Product, Raw Material, Pharmaceutical Dosage Form, Drug Delivery Mode, End User, and Count...

North America pharmaceutical packaging market is expected to grow by 6.4% annually in the forecast period and reach $41.88 billion by 2027 owing to the increase in healthcare coverage, growing aging population, an increase in non-communicable disease, new drug development and government initiatives ...

44407 | Healthcare and Social Assistance

Global Pharmaceutical Packaging Market 2020-2027 by Packaging Category (Primary, Secondary, Tertiary), Product, Raw Material, Pharmaceutical Dosage Form, Drug Delivery Mode, End User, and Region: Tren...

Global pharmaceutical packaging market will reach $151.08 billion by 2027, growing by 6.8% annually over 2020-2027 owing to the increase in healthcare coverage, growing aging population, an increase in non-communicable disease, new drug development and government initiatives to promote innovations i...

44407 | Healthcare and Social Assistance

Asia Pacific Organ-on-Chip Market 2020-2030 by Offering (Chips, Service), Organ Type (Liver, Heart, Lung, Kidney, Brain, Skin), Material (Polymers, Glass, Silicon), Application, End User, and Country:...

Asia Pacific organ-on-chip market will grow by 35.1% annually with a total addressable market cap of $399.4 million over 2021-2030 owing to the rising use of organ-on-a-chip (OOC) in early detection of drug toxicity, increasing demand for personalized medicine, the emergence of OOC as an alternative...

44407 | Healthcare and Social Assistance

Europe Organ-on-Chip Market 2020-2030 by Offering (Chips, Service), Organ Type (Liver, Heart, Lung, Kidney, Brain, Skin), Material (Polymers, Glass, Silicon), Application, End User, and Country: Trend...

Europe organ-on-chip market accounted for $6.9 million in 2020 and will grow by 32.2% annually over 2020-2030 owing to the rising use of organ-on-a-chip (OOC) in early detection of drug toxicity, increasing demand for personalized medicine, the emergence of OOC as an alternative to animal testing, t...

44407 | Healthcare and Social Assistance

North America Organ-on-Chip Market 2020-2030 by Offering (Chips, Service), Organ Type (Liver, Heart, Lung, Kidney, Brain, Skin), Material (Polymers, Glass, Silicon), Application, End User, and Country...

North America organ-on-chip market is expected to grow by 33.7% annually in the forecast period and reach $178.6 million by 2030 owing to the rising use of organ-on-a-chip (OOC) in early detection of drug toxicity, increasing demand for personalized medicine, the emergence of OOC as an alternative t...

44407 | Healthcare and Social Assistance

Global Organ-on-Chip Market 2020-2030 by Offering (Chips, Service), Organ Type (Liver, Heart, Lung, Kidney, Brain, Skin), Material (Polymers, Glass, Silicon), Application, End User, and Region: Trend ...

Global organ-on-chip market will reach $420.6 million by 2030, growing by 33.5% annually over 2020-2030 owing to the rising use of organ-on-a-chip (OOC) in early detection of drug toxicity, increasing demand for personalized medicine, the emergence of OOC as an alternative to animal testing, the sig...

44407 | Healthcare and Social Assistance

Asia Pacific Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, P...

Asia Pacific multiple sclerosis drugs market will grow by 6.5% annually with a total addressable market cap of $33.56 billion over 2120-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. H...

44407 | Healthcare and Social Assistance

Europe Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parente...

Europe multiple sclerosis drugs market accounted for $5,668.0 million in 2020 and will grow by 4.2% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. Highlighted with 3...

44407 | Healthcare and Social Assistance

North America Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, ...

North America multiple sclerosis drugs market is expected to grow by 3.8% annually in the forecast period and reach $15.65 billion by 2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. Hig...

44407 | Healthcare and Social Assistance

Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parente...

Global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. Highlighted with 87 tables a...

44407 | Healthcare and Social Assistance

First
Previous
1
2
3
4
5
6
7
8
9
10
Next

North America pharmaceutical packaging market is expected to grow by 6.4% annually in the forecast period and reach $41.88 billion by 2027 owing to the increase in healthcare coverage, growing aging population, an increase in non-communicable disease, new drug development and government initiatives to promote innovations in the pharmaceutical industry. Highlighted with 26 tables and 62 figures, this 111-page report “North America Pharmaceutical Packaging Market 2020-2027 by Packaging Category (Primary, Secondary, Tertiary), Product, Raw Material, Pharmaceutical Dosage Form, Drug Delivery Mode, End User, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire North America pharmaceutical packaging market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical packaging market in every aspect of the classification from perspectives of Packaging Category, Product, Raw Material, Pharmaceutical Dosage Form, Drug Delivery Mode, End User, and Country. Based on Packaging Category, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Primary Packaging • Secondary Packaging • Tertiary Packaging Based on Product, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Plastic Bottles • Blister Packs • Pre-Filled Syringes • Closures & Caps • Secondary Containers • Labels • Packaging Accessories • Other Products Based on Raw Material, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Plastics & Polymers • Paper & Paperboards • Glass • Metal • Other Materials Based on Pharmaceutical Dosage Form, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Liquid Dosage • Solid Dosage • Semi-solid and Pressurized Products • Other Pharmaceutical Dosage Forms Based on Drug Delivery Mode, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Oral Drug Delivery • Injectables • IV Drugs Delivery • Topical Drug Delivery • Transdermal Drug Delivery • Pulmonary Drug Delivery • Nasal Drug Delivery • Ocular Drug Delivery • Other Drugs Delivery Modes Based on End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Pharmaceutical Manufacturers • Contract Packaging Companies • Retail Pharmacies • Other End Users Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Packaging Category, Product, and Raw Material over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Amcor PLC AptarGroup, Inc. Becton, Dickinson and Company Berry North America Group, Inc. Catalent, Inc. Gerresheimer AG O-I Glass, Inc. (Owens Illinois, Inc.) Schott AG West Pharmaceutical Services, Inc. WestRock Company (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

Global pharmaceutical packaging market will reach $151.08 billion by 2027, growing by 6.8% annually over 2020-2027 owing to the increase in healthcare coverage, growing aging population, an increase in non-communicable disease, new drug development and government initiatives to promote innovations in the pharmaceutical industry. Highlighted with 85 tables and 95 figures, this 171-page report “Global Pharmaceutical Packaging Market 2020-2027 by Packaging Category (Primary, Secondary, Tertiary), Product, Raw Material, Pharmaceutical Dosage Form, Drug Delivery Mode, End User, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global pharmaceutical packaging market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global pharmaceutical packaging market in every aspect of the classification from perspectives of Packaging Category, Product, Raw Material, Pharmaceutical Dosage Form, Drug Delivery Mode, End User, and Region. Based on Packaging Category, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Primary Packaging • Secondary Packaging • Tertiary Packaging Based on Product, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Plastic Bottles • Blister Packs • Pre-Filled Syringes • Closures & Caps • Secondary Containers • Labels • Packaging Accessories • Other Products Based on Raw Material, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Plastics & Polymers • Paper & Paperboards • Glass • Metal • Other Materials Based on Pharmaceutical Dosage Form, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Liquid Dosage • Solid Dosage • Semi-solid and Pressurized Products • Other Pharmaceutical Dosage Forms Based on Drug Delivery Mode, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Oral Drug Delivery • Injectables • IV Drugs Delivery • Topical Drug Delivery • Transdermal Drug Delivery • Pulmonary Drug Delivery • Nasal Drug Delivery • Ocular Drug Delivery • Other Drugs Delivery Modes Based on End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Pharmaceutical Manufacturers • Contract Packaging Companies • Retail Pharmacies • Other End Users Geographically, the following regions together with the listed national/local markets are fully investigated: • North America (U.S., Canada, and Mexico) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (UAE, Saudi Arabia, South Africa) For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Packaging Category, Product, and Raw Material over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Amcor PLC AptarGroup, Inc. Becton, Dickinson and Company Berry Global Group, Inc. Catalent, Inc. Gerresheimer AG O-I Glass, Inc. (Owens Illinois, Inc.) Schott AG West Pharmaceutical Services, Inc. WestRock Company (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

Asia Pacific organ-on-chip market will grow by 35.1% annually with a total addressable market cap of $399.4 million over 2021-2030 owing to the rising use of organ-on-a-chip (OOC) in early detection of drug toxicity, increasing demand for personalized medicine, the emergence of OOC as an alternative to animal testing, the significant increase in research funding and venture capital investments. Highlighted with 30 tables and 50 figures, this 105-page report “Asia Pacific Organ-on-Chip Market 2020-2030 by Offering (Chips, Service), Organ Type (Liver, Heart, Lung, Kidney, Brain, Skin), Material (Polymers, Glass, Silicon), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific organ-on-chip market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific organ-on-chip market in every aspect of the classification from perspectives of Offering, Organ Type, Material, Application, End User, and Country. Based on Offering, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Chips • Service Based on Organ Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Liver-on-a-Chip • Heart-on-a-Chip • Lung-on-a-Chip • Kidney-on-a-Chip • Brain-on-a-Chip • Skin-on-a-Chip • Vessels-on-a-Chip • Other Organ Types Based on Material, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Polymers • Glass • Silicon Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Drug Discovery • Toxicology Research • Other Applications Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Pharmaceutical and Biotechnology Companies • Academic and Research Institutes • Cosmetics Industry • Other End Users Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Organ Type, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AxoSim Inc. BiomimX SRL Cherry Biotech CN Bio Innovations, Ltd. Emulate Inc. Hurel Corporation InSphero AG Kirkstall, Ltd. MIMETAS BV Nortis Inc. Organovo, Inc. SynVivo, Inc. Tara Biosystems Inc. TissUse GmbH (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

Europe organ-on-chip market accounted for $6.9 million in 2020 and will grow by 32.2% annually over 2020-2030 owing to the rising use of organ-on-a-chip (OOC) in early detection of drug toxicity, increasing demand for personalized medicine, the emergence of OOC as an alternative to animal testing, the significant increase in research funding and venture capital investments. Highlighted with 33 tables and 51 figures, this 106-page report “Europe Organ-on-Chip Market 2020-2030 by Offering (Chips, Service), Organ Type (Liver, Heart, Lung, Kidney, Brain, Skin), Material (Polymers, Glass, Silicon), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe organ-on-chip market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe organ-on-chip market in every aspect of the classification from perspectives of Offering, Organ Type, Material, Application, End User, and Country. Based on Offering, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Chips • Service Based on Organ Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Liver-on-a-Chip • Heart-on-a-Chip • Lung-on-a-Chip • Kidney-on-a-Chip • Brain-on-a-Chip • Skin-on-a-Chip • Vessels-on-a-Chip • Other Organ Types Based on Material, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Polymers • Glass • Silicon Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Drug Discovery • Toxicology Research • Other Applications Based on End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Pharmaceutical and Biotechnology Companies • Academic and Research Institutes • Cosmetics Industry • Other End Users Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Organ Type, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AxoSim Inc. BiomimX SRL Cherry Biotech CN Bio Innovations, Ltd. Emulate Inc. Hurel Corporation InSphero AG Kirkstall, Ltd. MIMETAS BV Nortis Inc. Organovo, Inc. SynVivo, Inc. Tara Biosystems Inc. TissUse GmbH (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

North America organ-on-chip market is expected to grow by 33.7% annually in the forecast period and reach $178.6 million by 2030 owing to the rising use of organ-on-a-chip (OOC) in early detection of drug toxicity, increasing demand for personalized medicine, the emergence of OOC as an alternative to animal testing, the significant increase in research funding and venture capital investments. Highlighted with 23 tables and 47 figures, this 99-page report “North America Organ-on-Chip Market 2020-2030 by Offering (Chips, Service), Organ Type (Liver, Heart, Lung, Kidney, Brain, Skin), Material (Polymers, Glass, Silicon), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire North America organ-on-chip market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America organ-on-chip market in every aspect of the classification from perspectives of Offering, Organ Type, Material, Application, End User, and Country. Based on Offering, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Chips • Service Based on Organ Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Liver-on-a-Chip • Heart-on-a-Chip • Lung-on-a-Chip • Kidney-on-a-Chip • Brain-on-a-Chip • Skin-on-a-Chip • Vessels-on-a-Chip • Other Organ Types Based on Material, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Polymers • Glass • Silicon Based on Application, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Drug Discovery • Toxicology Research • Other Applications Based on End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Pharmaceutical and Biotechnology Companies • Academic and Research Institutes • Cosmetics Industry • Other End Users Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Organ Type, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AxoSim Inc. BiomimX SRL Cherry Biotech CN Bio Innovations, Ltd. Emulate Inc. Hurel Corporation InSphero AG Kirkstall, Ltd. MIMETAS BV Nortis Inc. Organovo, Inc. SynVivo, Inc. Tara Biosystems Inc. TissUse GmbH (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

Global organ-on-chip market will reach $420.6 million by 2030, growing by 33.5% annually over 2020-2030 owing to the rising use of organ-on-a-chip (OOC) in early detection of drug toxicity, increasing demand for personalized medicine, the emergence of OOC as an alternative to animal testing, the significant increase in research funding and venture capital investments. Highlighted with 82 tables and 83 figures, this 160-page report “Global Organ-on-Chip Market 2020-2030 by Offering (Chips, Service), Organ Type (Liver, Heart, Lung, Kidney, Brain, Skin), Material (Polymers, Glass, Silicon), Application, End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global organ-on-chip market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global organ-on-chip market in every aspect of the classification from perspectives of Offering, Organ Type, Material, Application, End User, and Region. Based on Offering, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Chips • Service Based on Organ Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Liver-on-a-Chip • Heart-on-a-Chip • Lung-on-a-Chip • Kidney-on-a-Chip • Brain-on-a-Chip • Skin-on-a-Chip • Vessels-on-a-Chip • Other Organ Types Based on Material, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Polymers • Glass • Silicon Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Drug Discovery • Toxicology Research • Other Applications Based on End User, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section. • Pharmaceutical and Biotechnology Companies • Academic and Research Institutes • Cosmetics Industry • Other End Users Geographically, the following regions together with the listed national/local markets are fully investigated: • North America (U.S., Canada, and Mexico) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (UAE, Saudi Arabia, South Africa) For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Organ Type, Application, and End User over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): AxoSim Inc. BiomimX SRL Cherry Biotech CN Bio Innovations, Ltd. Emulate Inc. Hurel Corporation InSphero AG Kirkstall, Ltd. MIMETAS BV Nortis Inc. Organovo, Inc. SynVivo, Inc. Tara Biosystems Inc. TissUse GmbH (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

Asia Pacific multiple sclerosis drugs market will grow by 6.5% annually with a total addressable market cap of $33.56 billion over 2120-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. Highlighted with 35 tables and 54 figures, this 110-page report “Asia Pacific Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Country. Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Immunomodulators o Copaxone o Avonex/Plegridy o Gilneya o Tysabri o Betaseron/Extavia o Tecifidera o Rebif o Ampyra o Other Immunomodulators • Immunosuppressants o Aubagio o Lemtrada o Ocrelizumab o Zinbryta o Other Immunosuppressants Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Monoclonal Antibodies • Interferon Beta • Sphingosine 1 Phosphate Receptor Modulators • Mixed Polymers • NF-κB Inhibitor • Pyrimidine Synthesis Inhibitor • Corticosteroids • Adrenocorticotropic Hormone • Other Drug Classes Based on Drug Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Large-molecule Drugs • Small-molecule Drugs Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Oral Administration • Parenteral Administration Based on MS Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Relapsing-remitting MS (RRMS) • Primary-progressive MS (PPMS) • Secondary-progressive MS (SPMS) • Progressive-relapsing MS (PRMS) Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Geographically, the following national/local markets are fully investigated: • Japan • China • South Korea • Australia • India • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbvie, Inc. Acorda Therapeutics Inc. Bayer AG Biogen Inc. Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. Merck KgaA Mylan NV Novartis AG Pfizer Inc. Sanofi SA Teva Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

Europe multiple sclerosis drugs market accounted for $5,668.0 million in 2020 and will grow by 4.2% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. Highlighted with 38 tables and 55 figures, this 111-page report “Europe Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Europe multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Country. Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Immunomodulators o Copaxone o Avonex/Plegridy o Gilneya o Tysabri o Betaseron/Extavia o Tecifidera o Rebif o Ampyra o Other Immunomodulators • Immunosuppressants o Aubagio o Lemtrada o Ocrelizumab o Zinbryta o Other Immunosuppressants Based on Drug Class, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Monoclonal Antibodies • Interferon Beta • Sphingosine 1 Phosphate Receptor Modulators • Mixed Polymers • NF-κB Inhibitor • Pyrimidine Synthesis Inhibitor • Corticosteroids • Adrenocorticotropic Hormone • Other Drug Classes Based on Drug Category, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Large-molecule Drugs • Small-molecule Drugs Based on Route of Administration, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Oral Administration • Parenteral Administration Based on MS Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Relapsing-remitting MS (RRMS) • Primary-progressive MS (PPMS) • Secondary-progressive MS (SPMS) • Progressive-relapsing MS (PRMS) Based on Distribution Channel, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Geographically, the following national/local markets are fully investigated: • Germany • UK • France • Spain • Italy • Russia • Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbvie, Inc. Acorda Therapeutics Inc. Bayer AG Biogen Inc. Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. Merck KgaA Mylan NV Novartis AG Pfizer Inc. Sanofi SA Teva Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

North America multiple sclerosis drugs market is expected to grow by 3.8% annually in the forecast period and reach $15.65 billion by 2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. Highlighted with 28 tables and 51 figures, this 104-page report “North America Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire North America multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Country. Based on Drug Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Immunomodulators o Copaxone o Avonex/Plegridy o Gilneya o Tysabri o Betaseron/Extavia o Tecifidera o Rebif o Ampyra o Other Immunomodulators • Immunosuppressants o Aubagio o Lemtrada o Ocrelizumab o Zinbryta o Other Immunosuppressants Based on Drug Class, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Monoclonal Antibodies • Interferon Beta • Sphingosine 1 Phosphate Receptor Modulators • Mixed Polymers • NF-κB Inhibitor • Pyrimidine Synthesis Inhibitor • Corticosteroids • Adrenocorticotropic Hormone • Other Drug Classes Based on Drug Category, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Large-molecule Drugs • Small-molecule Drugs Based on Route of Administration, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Oral Administration • Parenteral Administration Based on MS Type, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Relapsing-remitting MS (RRMS) • Primary-progressive MS (PPMS) • Secondary-progressive MS (SPMS) • Progressive-relapsing MS (PRMS) Based on Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Geographically, the following national/local markets are fully investigated: • U.S. • Canada • Mexico For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbvie, Inc. Acorda Therapeutics Inc. Bayer AG Biogen Inc. Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. Merck KgaA Mylan NV Novartis AG Pfizer Inc. Sanofi SA Teva Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

Global multiple sclerosis drugs market will reach $29.97 billion by 2027, growing by 4.3% annually over 2020-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs. Highlighted with 87 tables and 87 figures, this 163-page report “Global Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Region. Based on Drug Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Immunomodulators o Copaxone o Avonex/Plegridy o Gilneya o Tysabri o Betaseron/Extavia o Tecifidera o Rebif o Ampyra o Other Immunomodulators • Immunosuppressants o Aubagio o Lemtrada o Ocrelizumab o Zinbryta o Other Immunosuppressants Based on Drug Class, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Monoclonal Antibodies • Interferon Beta • Sphingosine 1 Phosphate Receptor Modulators • Mixed Polymers • NF-κB Inhibitor • Pyrimidine Synthesis Inhibitor • Corticosteroids • Adrenocorticotropic Hormone • Other Drug Classes Based on Drug Category, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Large-molecule Drugs • Small-molecule Drugs Based on Route of Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Oral Administration • Parenteral Administration Based on MS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Relapsing-remitting MS (RRMS) • Primary-progressive MS (PPMS) • Secondary-progressive MS (SPMS) • Progressive-relapsing MS (PRMS) Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section. • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies Geographically, the following regions together with the listed national/local markets are fully investigated: • North America (U.S., Canada, and Mexico) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland) • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines) • South America (Brazil, Chile, Argentina, Rest of South America) • MEA (UAE, Saudi Arabia, South Africa) For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Key Players (this may not be a complete list and extra companies can be added upon request): Abbvie, Inc. Acorda Therapeutics Inc. Bayer AG Biogen Inc. Bristol-Myers Squibb Company F. Hoffmann-La Roche Ltd. Merck KgaA Mylan NV Novartis AG Pfizer Inc. Sanofi SA Teva Pharmaceutical Industries Ltd. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) ...

44407

LATEST REPORTS

PRESS RELEASES

Use Code

SDMR20

Purchase any report

AVAIL FLAT DISCOUNT